Invasive Fungal Infections Surveillance Initiative

This study is currently recruiting participants.

Verified by University of Pittsburgh, December 2008

Sponsors and Collaborators:	University of Pittsburgh Astellas Pharma US, Inc.
Information provided by:	University of Pittsburgh
ClinicalTrials.gov Identifier:	NCT00177944

Purpose

The purpose of this study is to optimize the management of patients treated for IFIs (invasive fungal infections) by establishing a real-time, continuous clinical data base that will capture and monitor trends in the epidemiology, diagnosis, treatment and outcomes of IFIs; reflect routine clinical management of patients with IFIs in order to evaluate treatment and provide a rationale for future treatment paradigms; and allow physicians to assess adherence to institutional clinical practice guidelines, validate current standardized definitions for patients with IFIs and promote change where appropriate.

Condition
Fungal Infection

MedlinePlus related topics: Fungal Infections Molds

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Prospective
Official Title:	Invasive Fungal Infections Surveillance Initiative

Further study details as provided by University of Pittsburgh:

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	500
Study Start Date:	August 2005
Estimated Study Completion Date:	December 2012

Groups/Cohorts
patients with funal infections

Detailed Description:

Gender, height, weight, ethnicity, antifungal treatment, fungal colonization, laboratory results, past medical history, IFI diagnosis, medications, outcomes

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

patients with funal infections

Criteria

Inclusion Criteria:

All patients with a diagnosis of proven or probable IFI. This includes patients with proven or probable invasive mold infections as well as patients with proven candidemia.

Exclusion Criteria:

All patients with a diagnosis of possible IFI. This includes patients with possible mold infections as well as patients with possible candidemia.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00177944

Contacts

Contact: David Paterson, MD	412-648-6401	patersond@dom.pitt.edu
Contact: Diana Pakstis, RN, BSN	412-648-6401	pakstisdl@dom.pitt.edu

Locations

United States, Pennsylvania
University of Pittsburgh Medical Center	Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: David Paterson, MD 412-648-6401 patersond@dom.pitt.edu
Contact: Diana Pakstis, RN, BSN 412-648-6401 Pakstisdl@dom.pitt.edu
Principal Investigator: David Paterson, MD

Sponsors and Collaborators

University of Pittsburgh

Astellas Pharma US, Inc.

Investigators

Principal Investigator:

David Paterson, MD

University of Pittsburgh

More Information

Responsible Party:	UPMC ( David Paterson, MD )
Study ID Numbers:	IRB # 0503062
Study First Received:	September 13, 2005
Last Updated:	December 16, 2008
ClinicalTrials.gov Identifier:	NCT00177944
Health Authority:	United States: Institutional Review Board

Keywords provided by University of Pittsburgh:

invasive fungal infection

Study placed in the following topic categories:

Mycoses

Additional relevant MeSH terms:

Communicable Diseases
Infection

ClinicalTrials.gov processed this record on January 16, 2009